Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Deals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies

Fineline Cube Sep 18, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...

Company Drug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Fineline Cube Sep 18, 2025

A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...

Company Deals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

Fineline Cube Sep 18, 2025

Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...

Drug Policy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Fineline Cube Sep 18, 2025

The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...

Company Deals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Fineline Cube Sep 18, 2025

Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...

Company Deals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Fineline Cube Sep 17, 2025

Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...

Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

Fineline Cube Sep 17, 2025

Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...

Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Fineline Cube Sep 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...

Company Drug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Fineline Cube Sep 17, 2025

Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...

Company Deals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Fineline Cube Sep 17, 2025

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...

Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

Fineline Cube Sep 17, 2025

The Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission jointly announced the “Administrative...

Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Fineline Cube Sep 17, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...

Company Drug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Fineline Cube Sep 17, 2025

Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...

Company Deals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Fineline Cube Sep 17, 2025

InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...

Company Deals Drug

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Fineline Cube Sep 17, 2025

Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson & Johnson (J&J,...

Company Deals

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Fineline Cube Sep 17, 2025

Shenzhen Mindray Bio‑Medical Electronics Co. has confirmed that Huatai Securities and JPMorgan Chase & Co. are the...

Company Deals

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio

Fineline Cube Sep 17, 2025

Duoning Biotechnology Co., Ltd. announced a strategic partnership with Upstream Bio Inc., granting Duoning an...

Drug

CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease

Fineline Cube Sep 17, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that...

Company Drug

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial

Fineline Cube Sep 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has been...

Company Drug

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments

Fineline Cube Sep 17, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...

Posts pagination

1 … 42 43 44 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.